Overweight or obese HIV-positive people randomized to an internet behavioral weight-loss program lost significantly more weight than those randomized to an internet educational program.
Two new monoclonal antibodies demonstrated success in helping people living with HIV suppress their viral loads to undetectable levels.
Low body mass index and obesity, but not being overweight, predicted mortality and serious non-AIDS events, including cardiovascular disease and cancers, in a 41,149-person D:A:D study analysis.
While antiretroviral therapy in pregnancy reduced vertical transmission, it also increased the frequency of several adverse birth outcomes compared with antenatal zidovudine (AZT) alone.
Several studies at CROI 2017 reported a similar conclusion: reducing ART to dolutegravir monotherapy should be stopped.
Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimzation studies.
Avoiding traditional cardiovascular risk factors -- high total cholesterol, hypertension and smoking -- would have the biggest impact on cutting myocardial infarction (MI) rates in North Americans with HIV.
Two doses of a therapeutic HIV vaccine plus three infusions of romidepsin, an HIV latency reactivator, allowed five of 13 trial participants to stay off antiretroviral therapy without rebound for up to 28 weeks in a Spanish proof-of-concept study....
We asked care providers, researchers and community leaders what their message to the Trump administration would be regarding the fight against HIV.
Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study
HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.